Last reviewed · How we verify
Endo — Portfolio Competitive Intelligence Brief
NDOI (NASDAQ)
7 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Gocovri | AMANTADINE | marketed | Influenza A M2 Protein Inhibitor | Sigma non-opioid intracellular receptor 1 | Immunology | 1968-01-01 |
| Valpin | octatropine methylbromide | marketed | octatropine methylbromide | Muscarinic acetylcholine receptor M1 | Neuroscience | 1962-01-01 |
| Valpin | ANISOTROPINE METHYLBROMIDE | marketed | octatropine methylbromide | Muscarinic acetylcholine receptor M1 | Pain | 1962-01-01 |
| Opana Er | OXYMORPHONE | marketed | Opioid Agonist | Mu-type opioid receptor | Neuroscience | 1959-01-01 |
| Xyosted (Autoinjector) | testosterone enantate | marketed | Androgen | Androgen receptor | Oncology | 1953-01-01 |
| Norgesic | acetylsalicylic acid | marketed | centrally acting muscle relaxant with anticholinergic properties | reticular formation (brain stem) | Immunology | 1950-01-01 |
| Hycodan | METHYLHOMATROPINE | marketed | methylhomatropine | Gastroenterology | 1943-01-01 |
Therapeutic area mix
- Immunology · 2
- Neuroscience · 2
- Gastroenterology · 1
- Oncology · 1
- Pain · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
- — Xyosted (Autoinjector) · 8021335 · US
- — Xyosted (Autoinjector) · 11497753 · US
- — Xyosted (Autoinjector) · 10279131 · US
- — Xyosted (Autoinjector) · 10357609 · US
- — Xyosted (Autoinjector) · 11446440 · US
- — Xyosted (Autoinjector) · 10905827 · US
- — Norgesic · 10646431 · US
- — Norgesic · 9216150 · US
- — Norgesic · 9226892 · US
- — Norgesic · 10786444 · US
- — Norgesic · 9987231 · US
- — Norgesic · 9539214 · US
- — Xyosted (Autoinjector) · 10821072 · US
- — Xyosted (Autoinjector) · 10881798 · US
- — Xyosted (Autoinjector) · 11160751 · US
- — Xyosted (Autoinjector) · 10912782 · US
- — Xyosted (Autoinjector) · 10238662 · US
- — Xyosted (Autoinjector) · 11191908 · US
- — Xyosted (Autoinjector) · 9744302 · US
- — Xyosted (Autoinjector) · 9950125 · US
- — Xyosted (Autoinjector) · 10646495 · US
Competitive overlap (companies sharing drug classes)
- · 2 shared drug classes
- Azurity · 1 shared drug class
- Bausch Health · 1 shared drug class
- Collegium Pharm Inc · 1 shared drug class
- Fresenius Kabi · 1 shared drug class
- Marius · 1 shared drug class
- Merck & Co. · 1 shared drug class
- Oregon Health and Science University · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Endo:
Cite this brief
Drug Landscape (2026). Endo — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/endo. Accessed 2026-05-13.